Ravindra Arya, MD, DM, is a clinical fellow in Pediatric Epilepsy. He has been a principal investigator for 2 clinical trials:

1. Intranasal versus Intravenous lorazepam for control of acute seizures in children: A randomized, open-label, non-inferiority study (NCT 00735527).

This trial showed non-inferiority of intranasal route for administration of lorazepam in children with acute convulsive seizures. In such children achieving timely venous access can be challenging and this study provided evidence for an alternative.

2. Oral folic acid supplementation for prevention of phenytoin induced gingival overgrowth: A randomized, double-blind, placebo-controlled study (NCT 00781196). 

Phenytoin is still the most common anti-seizure medication across the world, due to wide use in developing countries. Many children develop gingival overgrowth as an adverse effect, which has cosmetic and medical implications. This study provided class I evidence for preventive role of folic acid in this condition. 

He has also been co-investigator another clinical trial:

Effectiveness and safety of Donepezil in boys with Fragile-X syndrome: A randomized, double-blind, controlled study (Clinical Trials Registry of India 2008-000229).

Currently, he has an IRB approved protocol for studying “Language mapping by event related changes in high gamma spectral power during spontaneous conversation in patients with medically refractory epilepsy”